Medical
-
MannKind Corporation announced that a grant from Breakthrough T1D (formerly JDRF) will be used to support the Phase 2 INHALE-1ST trial of Afrezza in children aged 10 and up with a recent Type 1 diabetes diagnosis, which was initiated earlier… Read more . . .
-
Turin, Italy -based Kither Biotech says that a Phase 1 clinical study of its KIT2014 inhaled PDE3/4 inhibitor successfully demonstrated that the nebulized formulation was safe and well tolerated, with very limited systemic exposure. The… Read more . . .
-
SpliSense announced that it has secured up to $13 million in new funding from the Cystic Fibrosis Foundation to support an ongoing Phase 2 trial of SPL84 inhaled antisense oligonucleotide for the treatment of cystic… Read more . . .
-
MannKind Corporation announced the initiation of the Phase 2 INFLO-2 trial of its MNKD-201 nintedanib DPI in patients with idiopathic pulmonary fibrosis. The 12-week INFLO-2 study is expected to enroll approximately 210 IPF patients who… Read more . . .
-
SoftOx Solutions announced the initiation of its Phase 1 SIS-02 study of SIS hypochlorous acid inhalation solution in healthy volunteers as part of a European Defense Fund-supported effort to develop the inhalation solution as a… Read more . . .
-
Quince Therapeutics announced that it has agreed to acquire Orphai Therapeutics (formerly AI Therapeutics, formerly LAM Therapeutics) and its LAM-001 inhaled dry powder rapamycin (sirolimus) for $115 million up front and up to an additional… Read more . . .
-
Vertex has stopped a Phase 1/2 study of VX-522 inhaled RNA therapy for the treatment of cystic fibrosis and has ceased development of the product, the company said in its most recent report of financial… Read more . . .
-
Insilico Medicine, which has facilities in the US and China, said that an IND for a Phase 1 PK trial of rentosertib (ISM001-055) inhalation solution has been cleared by the CDE. The company said that… Read more . . .
-
Oragenics said that it has initiated a Phase 2a trial of ONP-002, a dry powder intranasal neurosteroid, for the treatment of mild traumatic brain injury in Australia after receiving approval from the Human Research Ethics… Read more . . .
-
According to Dompé, researchers at the Agostino Gemelli IRCCS University Hospital in Rome, Italy have initiated a Phase 2 trial of Dompé’s intranasal formulation of cenegermin-bkbj, a recombinant human nerve growth factor, in patients with… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland